Investigating how SARS-CoV-2 can develop resistance to antiviral treatments
Multidisciplinary studies on overcoming SARS-CoV-2 main protease drug resistance and on fitness costs
This study is looking at how the COVID-19 virus can change in ways that make it harder to treat with antiviral medications like Paxlovid, so we can find better treatment options for patients in the future.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11071374 on NIH RePORTER |
What this research studies
This research focuses on understanding how the SARS-CoV-2 virus, responsible for COVID-19, can develop resistance to antiviral drugs like Paxlovid. The study examines the main protease of the virus, which is crucial for its replication, and how mutations can affect the virus's ability to be treated effectively. By identifying specific mutations that confer resistance, the research aims to inform the development of new antiviral therapies that can overcome these challenges. Patients may benefit from improved treatment options as a result of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been treated for COVID-19 and may have developed resistance to current antiviral therapies.
Not a fit: Patients who have not been infected with SARS-CoV-2 or those who are not undergoing antiviral treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective antiviral treatments for COVID-19.
How similar studies have performed: Other research has shown success in understanding viral resistance mechanisms, indicating that this approach has potential for meaningful advancements.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Neilsen, Grace — Emory University
- Study coordinator: Neilsen, Grace
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.